The content on this site is intended for healthcare professionals only
Talking to ecancer from the 55th meeting of the American Society of Haematology ( ASH ) in New Orleans, USA, Prof Peter Hillmen, The Leeds Teaching Hospitals NHS Trust, Leeds, UK, outlines the importance of considering co-morbidities in older patients with CLL. He reviews how current treatments can best be used in this patient cohort, and advises on their main limitations. Prof Hillmen also notes how clinicians should manage relapsed elderly patients.
Finally, Prof Hillmen outlines his highlights from ASH 2013, such as the trials of chlorambucil in combination with antibodies – and notes his excitement of the recent advances that have been made in CLL.
Read our our ASH 2013 conference report for free.
This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).
SIOG 2024: Updates in haematology
New classification for identifying HR myeloma based on cytogenetic abnormalities
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Use of bispecifics and CAR T cells in South America
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
Revolutionising multiple myeloma treatment with CAR T-Cell therapies
Advancements in paediatric Acute lymphoblastic leukemia management
